Search Results - "Waller, Allyson"

Hypertension and incident cardiovascular events following ibrutinib initiation by Dickerson, Tyler, Wiczer, Tracy, Waller, Allyson, Philippon, Jennifer, Porter, Kyle, Haddad, Devin, Guha, Avirup, Rogers, Kerry A., Bhat, Seema, Byrd, John C., Woyach, Jennifer A., Awan, Farrukh, Addison, Daniel

“…Ibrutinib is associated with dramatic efficacy against B-cell malignancies. Yet, it has been linked with potentially limiting cardiotoxicity, including…”
Get full text

Safety and Feasibility of Outpatient High-Dose Cytarabine Consolidation in AML Patients by Waller, Allyson, Brown, Shelly, Freeman, Tracelyn, Kumar, Pooja S., Mims, Alice S.

Get full text

Gemcitabine and Liposomal Doxorubicin (GemDox) for the Treatment of Relapsed and Refractory T-Cell Lymphomas by Braunstein, Zachary, Waller, Allyson, Dotson, Emily, McLaughlin, Eric, Hanel, Walter, Reneau, John C, Addison, Daniel, Porcu, Pierluigi, Brammer, Jonathan E.

“…Introduction: Aggressive T-cell lymphomas (TCL) account for 10-15% of non-Hodgkin's lymphomas and have lower rates of complete response (CR), overall response…”
Get full text

Gemcitabine and liposomal doxorubicin (GemDox) for the treatment of relapsed and refractory T-cell lymphomas by Braunstein, Zachary, Waller, Allyson, Dotson, Emily, McLaughlin, Eric, Hanel, Walter, Reneau, John, Addison, Daniel, Porcu, Pierluigi, Brammer, Jonathan Edward

“…Aggressive T-cell lymphomas (TCL) account for 10-15% of non-Hodgkin lymphomas (NHL) with weaker responses and shorter durations to chemotherapy than other…”
Get full text

Ninety-minute daratumumab infusion is safe in multiple myeloma by Barr, Hallie, Dempsey, Jessica, Waller, Allyson, Huang, Ying, Williams, Nita, Sharma, Nidhi, Benson, Don M., Rosko, Ashley E., Efebera, Yvonne A., Hofmeister, Craig C.

Get full text

Outpatient rapid 4-step desensitization for gynecologic oncology patients with mild to low-risk, moderate hypersensitivity reactions to carboplatin/cisplatin by Li, Quan, Cohn, David, Waller, Allyson, Backes, Floor, Copeland, Larry, Fowler, Jeffrey, Salani, Ritu, O'Malley, David

“…Abstract Objective The primary objective of this study is to assess the efficacy and safety of an outpatient, 4-step, one-solution desensitization protocol in…”
Get full text

Characterization of Comparative Clinical Outcomes and Molecular Features of Black Patients with Acute Promyelocytic Leukemia (APL) Reveals Similar Survival and Distinct Genomic Profiles by Habib, Alma, Boateng, Isaiah, Nicolet, Deedra, Mrózek, Krzysztof, Fisher, James L, Waller, Allyson, Stiff, Andrew, Buss, Jill, Laganson, Andrea, Martinez Corzine, Sienna, Hamp, Ethan, Abu-Shihab, Yazan, Powell, Bayard L, Uy, Geoffrey L, Stock, Wendy, Stone, Richard M, Kolitz, Jonathan E, Wang, Eunice S., Carroll, Andrew J, Tyner, Jeffrey W, Hantel, Andrew, Paskett, Electra D, Byrd, John C., Mardis, Elaine R, Plascak, Jesse J, Eisfeld, Ann-Kathrin

“…Introduction: Although APL, a subtype of acute myeloid leukemia (AML), is an aggressive disease, its treatment was revolutionized with combination all- trans…”
Get full text

Hypertension Development, Management, and Cardiovascular Events Following Ibrutinib Initiation for Hematologic Malignancies by Dickerson, Tyler, Wiczer, Tracy, Waller, Allyson, Philippon, Jennifer, Haddad, Devin, Guha, Avirup, Porter, Kyle, Rogers, Kerry A., Woyach, Jennifer A., Byrd, John C., Addison, Daniel, Awan, Farrukh T.

“…Background Ibrutinib (IB), a nonselective Bruton's tyrosine kinase inhibitor, is associated with significantly improved disease control rates, progression…”
Get full text

Ninety-Minute Daratumumab Infusion Is Safe in Multiple Myeloma by Barr, Hallie, Dempsey, Jessica, Waller, Allyson, Huang, Ying, Williams, Nita, Sharma, Nidhi, Benson, Don M, Rosko, Ashley E, Efebera, Yvonne A, Hofmeister, Craig C

“…▪ Background: Daratumumab, an anti-CD38 monoclonal antibody, was first approved for the treatment of relapsed and refractory multiple myeloma (MM) in December…”
Get full text

Real-World Experience of Adults With Acute Myeloid Leukemia on Hypomethylating Agents With or Without Venetoclax at a Comprehensive Cancer Center by Freeman, Tracelyn, Williams, Kiersten, Puto, Marcin, Waller, Allyson, McLaughlin, Eric M., Blachly, James S., Roddy, Julianna

Get full text